Genetic Technologies Ltd (GENE)

1.811
-0.029(-1.60%)
After Hours
1.800
-0.011(-0.585%)
- Real-time Data
  • Volume:
    40,924
  • Bid/Ask:
    1.840/1.900
  • Day's Range:
    1.800 - 1.900

GENE Overview

Prev. Close
1.811
Day's Range
1.8-1.9
Revenue
86.17K
Open
1.88
52 wk Range
1.77-6.47
EPS
-0.35
Volume
40,924
Market Cap
26.15M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
139,815
P/E Ratio
-
Beta
2.01
1-Year Change
-65.83%
Shares Outstanding
9,233,965,143
Next Earnings Date
-
What is your sentiment on Genetic Technologies Ltd?
or
Market is currently closed. Voting is open during market hours.

  • Genetic Technologies reports FQ2 cash flow results
    • BySeeking Alpha-

    Genetic Technologies reported FQ2 FY'22 cash balance of A$13.5M and increased customer receipts of A$1.8M further extending runway for growth.The company said ‘One company...

  • Genetic Tech expects Q2 cash receipts of A$1.8M
    • BySeeking Alpha-

    Genetic Technologies (GENE) expects cash receipts for Q2 of A$1.8M, a 112% increase sequentially following the integration of EasyDNA.In the coming quarters, the focus will be...

Genetic Technologies Ltd Company Profile

Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company focuses on the development and commercialization of genetic risk assessment technology for contracting cancer and other chronic diseases. The Company operates through two geographic segments: Australia and United states of America (USA). Australia segment is the home country of the parent entity and the location of the Company's genetic testing and licensing operations. USA segment is the home of Phenogen Sciences Inc. and GeneType Corporation. The Company’s products include GeneType for Breast Cancer is a test that can determine a woman's risk of developing sporadic breast cancer over a period of time; GeneType for Colorectal Cancer is a test that can determine a patient's risk of developing colorectal cancer over a period of time. The Company focuses on development its Germline testing division for hereditary testing.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Trading halt on ASX for GTG (the underlying stock of GENE) today - waiting for announcement regardig the Covid-19 risk test.
    0
    • Trading halt expires 1st of June. Expect a statement from the company before this time.
      0
    • As expected. The Covid-19 test is now available via their US partner via Medicare and Mediaid.
      0
  • Commercial release of Covid19 risk test announced to be ready in US market before end of May.
    0
    • In the meantime - watch out for a coming spike when they launch their integration towards Medicare and Medicaid for their Covid-19 risk assessment test.
      0
      • If only GENE could make a gene-test that would tell if a patient will get an adverser reaction to the AstraZeneca vaccine towards Covid-19 - then they would have a winner!
        0
        • Finally - getting closer to the launch of Covid-19 Risk test in the US market. See announcement today
          0
          • Nice... :)
            0
            • Whats up?
              0
              • oversold
                0
            • seems like the market in general did not get the story about the distribution agreement for USA for the Covid-19 risk test.
              1
              • untill the next earning report day...
                0
            • There is good news on GENE's website!
              0
              • Trade is stopped by the company. News will coming...
                0
                • good or bad news?
                  0
                • Casa Albufeira The want  announce in relation to a material distribution agreement. So good news. See Link:https://hotcopper.com.au/threads/ann-trading-halt.5938772/
                  0
                • Pira Mahendran muito obrigado..
                  0
              • no market today?!!!
                0
                • Very good opportunity to buy...
                  0
                  • Polygenic Covid Risk Assessment Kit is coming soon
                    0
                    • aqms
                      0
                      • sorry, wrong forum.. my mistake..
                        0
                    • Jan 28th is the key date
                      2
                      • Casa Albufeira‘The Company will provide an update on further advancements to its diagnostic tests and hold an investor webinar to discuss the quarterly update, on Thursday, January 28, 2021 at 11:30 AEDT’
                        0
                      • 0
                      • 0
                    • Any idea if I buy again today around 5$ could it rally tomorrow or coming week?
                      3
                      • News: https://finance.yahoo.com/news/genetic-technologies-provides-covid-19-120000548.html
                        0
                        • https://www.globenewswire.com/news-release/2021/01/21/2162005/0/en/Genetic-Technologies-Provides-Update-on-its-COVID-19-Disease-Severity-Risk-Test-and-Expansion-into-Germline-Testing.html
                          1
                          • Great today I can sell them
                            1
                            • Interesting.. Where do you hear of such stocks? I'm new to trading
                              0
                            • https://www.globenewswire.com/news-release/2021/01/21/2162005/0/en/Genetic-Technologies-Provides-Update-on-its-COVID-19-Disease-Severity-Risk-Test-and-Expansion-into-Germline-Testing.html
                              0
                            • COVID-19 test product available
                              0
                          • low float and on watch
                            0
                            • $5 by the end if fe
                              0
                              • The sudden race yesterday towards the end of the trading day (Nasdaq) was due to the annual report. GENE is a mirror stock of GTG on ASX (Australian Stock Exchange). Genetic Technologies Ltd is an Australian company.  The price of GTG on ASX is now (close to end of ASX trading day ) comparable to 4.49 USD for GENE. 1 GENE = 600 GTG,
                                1
                                • Scrivi ciò che penhttps://www.prweb.com/releases/taliaz_announces_ce_certification_for_its_predictix_digital_ai_mental_health_solution/prweb17597212.htmsi su Genetic Technologies Ltd
                                  0
                                  • Sudden race up and then a brutal drop downwards and a trade stop. What is happening?
                                    0
                                    • weird
                                      0
                                  • You're not alone @mr. risk, GENE has been my greatest ticker.
                                    0
                                    • Was wondering - alone in here at times...
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.